MediPharm Labs Corp. (MEDIF)
| Market Cap | 21.15M -0.3% |
| Revenue (ttm) | 29.19M -6.7% |
| Net Income | -3.50M |
| EPS | -0.01 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 0.0500 |
| Previous Close | 0.0500 |
| Day's Range | 0.0500 - 0.0500 |
| 52-Week Range | 0.0400 - 0.0755 |
| Beta | 0.93 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About MediPharm Labs
MediPharm Labs Corp. operates as a pharmaceutical company that produces and sells purified, pharmaceutical-like cannabis extracts, concentrates, active pharmaceutical ingredients, and advanced derivative products in Canada, Australia, Germany, and internationally. The company formulates, processes, packages, and distributes cannabis active ingredients and advanced cannabinoid-based products. It also provides good manufacturing practice flower sourcing, packaging, and distribution services, as well as dried flower, pre-roll, and other cannabis p... [Read more]
Financial Performance
In 2025, MediPharm Labs's revenue was 45.12 million, an increase of 7.54% compared to the previous year's 41.96 million. Losses were -8.27 million, -22.69% less than in 2024.
Financial numbers in CAD Financial StatementsNews
MediPharm Labs Earnings Call Transcript: Q2 2026
Q2 marked a return to profitability with positive net income and the strongest adjusted EBITDA since 2019, driven by international medical market growth, especially in Germany, and disciplined cost management. Gross margin reached 43%, and the balance sheet remains strong with nearly CAD 10 million in cash.
MediPharm Labs Registration statement: Q2 2026
MediPharm Labs filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
MediPharm Labs Registration statement: Q2 2026
MediPharm Labs filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
MediPharm Labs Earnings release: Q2 2026
MediPharm Labs released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
MediPharm Labs Reports Positive Q2 2026 Net Income and Second Consecutive Quarter of Positive Adjusted EBITDA
Q2 2026 Adjusted EBITDA1 of $0.9M, the Company's strongest quarterly performance since 20192 Positive net income in Q2 2026, compared with a net loss of $3.8M in Q2 2025 OPEX decreased 44% in Q2 2026 ...
MediPharm Labs Announces Positive Phase II LiBBY Trial Results Demonstrating Significant Reduction in Agitation Associated With Advanced Alzheimer's Disease and Dementia
TORONTO, July 14, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specializing in precisi...
MediPharm Labs Announces Voting Results from the 2026 Annual and Special Meeting of Shareholders
TORONTO, June 17, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precisio...
MediPharm Labs Reminds Shareholders of Upcoming Annual and Special Meeting
Annual and Special Meeting to be held virtually on Wednesday, June 17, 2026 at 11:00 a.m. (Eastern Time).
MediPharm Labs Earnings Call Transcript: Q1 2026
Q1 2026 saw positive adjusted EBITDA and strong gross margins despite lower revenue, with disciplined execution and international expansion driving performance. The company remains well-capitalized, focused on regulated medical markets, and is mitigating Canadian reimbursement headwinds.
MediPharm Labs Earnings release: Q1 2026
MediPharm Labs released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
MediPharm Labs Registration statement: Q1 2026
MediPharm Labs filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
MediPharm Labs Registration statement: Q1 2026
MediPharm Labs filed a registration statement on May 13, 2026, providing details about a securities offering with the SEC.
MediPharm Labs Reports First Quarter 2026 Results Achieving Positive Adjusted EBITDA
Q1 2026 Positive Adjusted EBITDA(1) Net Revenue of $9M with strong gross margins of 37% OPEX decreased 28% in Q1 2026 versus Q4 2025 Company is virtually debt free, with a Q1 ending cash balance of $9...
MediPharm Labs Sets Date to Report First Quarter 2026 Financial Results
TORONTO, May 07, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm", "MediPharm Labs" or the "Company") a pharmaceutical company specialized in precisio...
MediPharm Labs Positioned to Serve Growing U.S. Pharmaceutical and Clinical Research Demand Following Cannabis Rescheduling
On April 22, 2026, the U.S. Department of Justice and Drug Enforcement Administration's final order rescheduling FDA-approved cannabis drug products and state-licensed medical cannabis from Schedule I...
MediPharm Labs Earnings Call Transcript: Q4 2025
Full-year revenue grew 8% to CAD 45 million, led by a 42% increase in international medical cannabis, now over half of total revenue. Gross margin improved to 31%, and net loss narrowed to CAD 8.3 million. Strong balance sheet, no material debt, and continued focus on international growth.
MediPharm Labs Earnings release: Q4 2025
MediPharm Labs released its Q4 2025 earnings on March 30, 2026, summarizing the period's financial results.
MediPharm Labs Registration statement: Q4 2025
MediPharm Labs filed a registration statement on March 30, 2026, providing details about a securities offering with the SEC.
MediPharm Labs Registration statement: Q4 2025
MediPharm Labs filed a registration statement on March 30, 2026, providing details about a securities offering with the SEC.
MediPharm Labs Reports Full Year & Fourth Quarter 2025 Results with Over 40% Annual Growth in International Medical Revenue
FY 2025 revenue of $45.1 million, an increase of 8% over 2024 International Medical Cannabis revenue increased 43% year-over-year and represented more than 50% of total revenue Increased cash balance ...
MediPharm Labs Sets Date to Report Full Year and Fourth Quarter 2025 Financial Results
MediPharm Labs will release its financial results for the three & twelve months ended December 31st, 2025, before markets open on Monday, March 30th, 2026.
Medipharm Labs announces Pidduck to step down as CEO, Hunter named interim CEO
MediPharm Labs (MEDIF) announced that David Pidduck will be stepping down from his role as the Company’s Chief Executive Officer, CEO, effective January 23rd, 2026. The Board of Directors has…
MediPharm Labs Announces CEO Transition: David Pidduck to Step Down; CFO Greg Hunter Appointed Interim CEO
TORONTO, Jan. 19, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) ("MediPharm" or the "Company"), a pharmaceutical company specialized in precision-based cannabinoi...
Medipharm Labs enters supply agreement with Remidose
MediPharm Labs (MEDIF) announced the signing of a definitive supply agreement with Remidose Aerosols for the shipment of GMP-certified medicinal cannabis products to Costa Rica. Under the agreement, M...
MediPharm Labs to Enter New Market with Costa Rica Supply Agreement
TORONTO, Jan. 13, 2026 (GLOBE NEWSWIRE) -- MediPharm Labs Corp. (TSX: LABS) (OTCQB: MEDIF) (FSE: MLZ) (“MediPharm”, “MediPharm Labs” or the “Company”), a pharmaceutical company specialized in precisio...